WO2002040467A1 - Composes - Google Patents

Composes Download PDF

Info

Publication number
WO2002040467A1
WO2002040467A1 PCT/EP2001/013320 EP0113320W WO0240467A1 WO 2002040467 A1 WO2002040467 A1 WO 2002040467A1 EP 0113320 W EP0113320 W EP 0113320W WO 0240467 A1 WO0240467 A1 WO 0240467A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
disease
acceptable salt
compound
formula
Prior art date
Application number
PCT/EP2001/013320
Other languages
English (en)
Inventor
Laramie Mary Gaster
John David Harling
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to AU2002216043A priority Critical patent/AU2002216043A1/en
Publication of WO2002040467A1 publication Critical patent/WO2002040467A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • This invention relates to 2-pyridyl substituted benzimidazoles which are inhibitors of the transforming growth factor, (“TGF”)- ⁇ signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the type I or activm-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine, specifically to the treatment and prevention of a disease state mediated by this pathway.
  • TGF transforming growth factor
  • ALK activm-like kinase
  • TGF- ⁇ l is the prototypic member of a family of cytokines including the TGF- ⁇ s, activins, inhibins, bone morphogenetic proteins and Miillerian-inhibiting substance, that signal through a family of single transmembrane serine/threonine kinase receptors. These receptors can be divided in two classes, the type I or activin like kinase (ALK) receptors and type II receptors.
  • ALK activin like kinase
  • the ALK receptors are distinguished from the type II receptors in that the ALK receptors (a) lack the seririe/threonine rich intracellular tail, (b) possess serine/threonine kinase domains that are very homologous between type I receptors, and (c) share a common sequence motif called the GS domain, consisting of a region rich in glycine and serine residues.
  • the GS domain is at the amino terminal end of the intracellular kinase domain and is critical for activation by the type ⁇ receptor.
  • the type II receptor phosphorylates the GS domain of the type I receptor for TGF- ⁇ , ALK5, in the presence of TGF- ⁇ .
  • the ALK5 in turn, phosphorylates the cytoplasmic proteins smad2 and smad3 at two carboxy terminal serines.
  • the phosphorylated smad proteins translocate into the nucleus and activate genes that contribute to the production of extracellular matrix. Therefore, preferred compounds of this invention are selective in that they inhibit the type I receptor and thus matrix production.
  • TGF- ⁇ l Activation of the TGF- ⁇ l axis and expansion of extracellular matrix are early and persistent contributors to the development and progression of chronic renal disease and vascular disease. Border W.A., et al, N. Engl. J. Med., 1994; 331(19), 1286-92. Further, TGF- ⁇ l plays a role in the formation of fibronectin and plasminogen activator inhibitor- 1, components of sclerotic deposits, through the action of smad3 phosphorylation by the TGF- ⁇ l receptor ALK5. Zhang Y., et al, Nature, 1998; 394(6696), 909-13; Usui T., et al, Invest. Ophthalmol. Vis. Set, 1998; 39(11), 1981-9.
  • TGF- ⁇ l has been implicated in many renal fibrotic disorders. Border W.A., et al, N. Engl. J. Med., 1994; 331(19), 1286-92. TGF- ⁇ l is elevated in acute and chronic glomerulonephritis Yoshioka K., et al, Lab.
  • TGF- ⁇ l transgenic mice or in vivo transfection of the TGF- ⁇ l gene into normal rat kidneys resulted in the rapid development of glomerulosclerosis.
  • inhibition of TGF- ⁇ l activity is indicated as a therapeutic intervention in chronic renal disease.
  • TGF- ⁇ l and its receptors are increased in injured blood vessels and are indicated in neointima formation following balloon angioplasty Saltis J., et al, Clin. Exp. Pharmacol.
  • TGF- ⁇ l is a potent stimulator of smooth muscle cell (“SMC") migration in vitro and migration of SMC in the arterial wall is a contributing factor in the pathogenesis of atherosclerosis and restenosis.
  • SMC smooth muscle cell
  • ALK5 correlated with total cholesterol (P ⁇ 0.001) Blann A.D., et al, Atherosclerosis, 1996; 120(1-2), 221-6.
  • SMC derived from human atherosclerotic lesions have an increased ALK5/TGF- ⁇ type II receptor ratio.
  • TGF- ⁇ l is over-expressed in fibroproliferative vascular lesions, receptor- variant cells would be allowed to grow in a slow, but uncontrolled fashion, while overproducing extracellular matrix components McCaffrey T.A., et al, Jr., J. Clin. Invest., 1995; 96(6), 2667-75.
  • TGF- ⁇ l was immunolocalized to non-foamy macrophages in atherosclerotic lesions where active matrix synthesis occurs, suggesting that non-foamy macrophages may participate in modulating matrix gene expression in atherosclerotic remodeling via a TGF- ⁇ -dependent mechanism. Therefore, inhibiting the action of TGF- ⁇ l on ALK5 is also indicated in atherosclerosis and restenosis.
  • TGF- ⁇ is also indicated in wound repair.
  • Neutralizing antibodies to TGF- ⁇ l have been used in a number of models to illustrate that inhibition of TGF- ⁇ l signaling is beneficial in restoring function after injury by limiting excessive scar formation during the healing process.
  • neutralizing antibodies to TGF- ⁇ l and TGF- ⁇ 2 reduced scar formation and improved the cytoarchitecture of the neodermis by reducing the number of monocytes and macrophages as well as decreasing dermal fibronectin and collagen deposition in rats Shah M., J. Cell. Set, 1995, 108, 985-1002.
  • TGF- ⁇ antibodies also improve healing of corneal wounds in rabbits Moller-Pedersen T., Curr.
  • TGF- ⁇ is also implicated in peritoneal adhesions Saed G.M., et al, Wound Repair Regeneration, 1999 Nov-Dec, 7(6), 504-510. Therefore, inhibitors of ALK5 would be beneficial in preventing peritoneal and sub-dermal fibrotic adhesions following surgical procedures.
  • ALK5 kinase mechanisms such as chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis, liver fibrosis and renal fibrosis, and restenosis.
  • R 1 is phenyl or naphthyl optionally substituted with one or more substituents selecte from halo, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 alkyl, C ⁇ - 6 haloalkyl, -O-(CH 2 ) m -Ph, -S-(CH 2 ) m - Ph, cyano, phenyl, and CO 2 R, wherein R is hydrogen or Ci- ⁇ alkyl and m is 0-3; or phenyl fused with a 5- to 7-membered aromatic or non-aromatic ring wherein said ring contains up to three heteroatoms, independently selected from N, O and S; and
  • R 2 represents one or more substituents independently selected from C]- 6 alkyl, C ⁇ . 6 alkoxy, -ehaloalkyl, halo, NH 2 , NH-C ⁇ - 6 alkyl or NH(CH 2 ) endeavour-Ph wherein n is 0-3.
  • R 1 is preferably phenyl optionally substituted by halo, or R 1 is phenyl fused with a 5- to 7-membered aromatic or non-aromatic ring wherein said ring contains up to three heteroatoms, independently selected from N, O and S, for example R 1 may represent benzo[l,3]dioxolyl, 2,3- dihydrobenzo[l,4]dioxinyl, benzoxazolyl, benzothiazolyl, benzo[l,2,5]oxadiazolyl, benzo[l,2,5]thiadiazolyl or dihydrobenzofuranyl.
  • R 2 is preferably a single substituent.
  • R 2 is preferably methyl or halo, more preferably 6- methyl or 6-halo.
  • the compounds of formula (I) preferably have a molecular weight of less than 800.
  • Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts of the compounds of formula (I) include, but are not limited to, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate, or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate and stearate.
  • inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate
  • an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate and stearate.
  • Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed.
  • This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
  • Certain of the compounds of formula (T) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures.
  • the invention includes all such forms, in particular the pure isomeric forms.
  • the different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
  • the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably at least 10% of a compound of the formula (I) or pharmaceutically acceptable derivative thereof.
  • C ⁇ a-kyl as used herein whether on its own or as part of a larger group e.g. C ⁇ - 6 alkoxy, means a straight or branched chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl.
  • C ⁇ . 6 haloalkyl groups may contain one or more halo atoms, a particular C ⁇ - 6 haloalkyl group that may be mentioned in CF 3 .
  • halo or halogen are used interchangeably herein to mean radicals derived from the elements chlorine, fluorine, iodine and bromine.
  • cycloalkyl as used means cyclic radicals, preferably of 3 to 7 carbons, including but not limited to cyclopropyl, cyclopentyl and cyclohexyl.
  • ALK5 inhibitor means a compound, other than inhibitory smads, e.g. smad6 and smad7, which selectively inhibits the ALK5 receptor preferentially over p38 or type II receptors.
  • ALK5 mediated disease state means any disease state which is mediated (or modulated) by ALK5, for example a disease which is modulated by the inhibition of the phosphorylation of smad 2/3 in the TGF- ⁇ l signaling pathway.
  • ulcers as used herein includes but is not limited to, diabetic ulcers, chronic ulcers, gastric ulcers, and duodenal ulcers.
  • the compounds of formula (I) can be prepared by art-recognized procedures from known or commercially available starting materials. If the starting materials are unavailable from a commercial source, their synthesis is described herein, or they can be prepared by procedures known in the art.
  • Reaction of an aniline, R ⁇ NH 2 , in the presence of sodium hydride with l-fluoro-2- nitrobenzene affords an intermediate anilino-nitro-benzene which may be reduced to a bis-anilino compound using for example tin(U)chloride or catalytic hydrogenation. It will be appreciated that the choice of reducing agent will be influenced by the nature of Rj. Reaction of this bis- anilino compound with a pyridine-2-carboxaldehyde in the presence of copper(H)acetate affords benzimidazole compounds of formula (I) (Scheme 1).
  • a compound library comprising at least 2 compounds of formula (I) or pharmaceutically acceptable salts thereof.
  • a method of treating a disease mediated by the ALK5 receptor in mammals comprising administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • ALK5-mediated disease states include, but are not limited to, chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal abrasion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis, liver fibrosis, and renal fibrosis and restenosis.
  • treating is meant either prophylactic or therapeutic therapy.
  • a method of inhibiting the TGF- ⁇ signaling pathway in mammals for example, inhibiting the phosphorylation of smad2 or smad3 by the type I or activin-like kinase ALK5 receptor, which method comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of inhibiting matrix formation in mammals by inhibiting the TGF- ⁇ signalling pathway for example, inhibiting the phosphorylation of smad2 or smad3 by the type I or activin-like kinase ALK5 receptor, which method comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof may be administered in conventional dosage forms prepared by combining a compound of formula (I) with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • compositions of the invention may be formulated for administration by any route, and include those in a form adapted for oral, topical or parenteral administration to mammals including humans.
  • compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • the topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl 7-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or
  • Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • the dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.
  • the optimal quantity and spacing of individual dosages of a formula (I) compound will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the formula (I) compound given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. No toxicological effects are indicated when a compound of formula (I) or a pharmaceutically acceptable derivative thereof is administered in the above-mentioned dosage range.
  • Example 1 l-Benzo[l,3]dioxol-5-yl-2-pyridin-2-yl-l-H r -benzimidazole
  • PI loxymg, 0.43mmol
  • pyridine-2-carboxaldehyde 0.041ml, 0.43mmol
  • cupric acetate 80mg, 0.43mmol
  • the mixture was heated at reflux for 20 min.
  • an aqueous solution of the disodium salt of ethylenediamine tetraacetic acid (10ml, 0.1M) was added and stirred vigorously for 10 min.
  • the mixture was diluted with water and ethyl acetate.
  • the biological activity of the compounds may be assessed using the following assays: Method for evaluating ALK5 kinase phosphorylation of smad3
  • Inhibitors of ALK5 were evaluated by determining the activity of the enzyme in the presence of various compounds. Plates were incubated for 3 hours at 30°C. After incubation the assay buffer was removed by aspiration and the wells were washed 3 times with 200 microliter cold 10 millimolar sodium pyrophosphate in phosphate buffered saline. The last wash was aspirated and blotted plate dry. Plate was then counted on a Packard TopCount.
  • the compounds generally show ALK5 receptor modulator activity having IC50 values in the range of 0.0001 to 10 ⁇ M.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés à base de benzimidazole 2-pyridyle substitué, qui correspondent à la formule (I), dans laquelle R1 est phényle ou naphthyle éventuellement substitué par un ou plusieurs substituants sélectionnés parmi halo-, alcoxy C1-6, alkylthio C1-6, haloalkyle C1-6, -O-(CH2)m-Ph, -S-(CH2)m-Ph, cyano, phényle et CO2R, dans laquelle R est hydrogène ou alkyle C1-6 et m est 0-3; ou phényle fusionné avec un noyau aromatique ou non aromatique avec 5 à 7 éléments, ledit noyau contenant jusqu'à trois hétéroatomes, sélectionnés indépendamment parmi N, O et S; et R2 représente un ou plusieurs substituants sélectionnés indépendamment parmi alkyle C1-6, alcoxy C1-6, haloalkyle C1-6, halo-, NH2, alkyle NH-C1-6 ou NH(CH2)n-Ph, dans laquelle n est 0-3, ainsi que leurs sels et solvates, de même que des procédés pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en médecine.
PCT/EP2001/013320 2000-11-17 2001-11-15 Composes WO2002040467A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002216043A AU2002216043A1 (en) 2000-11-17 2001-11-15 Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028105.5A GB0028105D0 (en) 2000-11-17 2000-11-17 Compounds
GB0028105.5 2000-11-17

Publications (1)

Publication Number Publication Date
WO2002040467A1 true WO2002040467A1 (fr) 2002-05-23

Family

ID=9903382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/013320 WO2002040467A1 (fr) 2000-11-17 2001-11-15 Composes

Country Status (3)

Country Link
AU (1) AU2002216043A1 (fr)
GB (1) GB0028105D0 (fr)
WO (1) WO2002040467A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000817A2 (fr) * 2002-06-24 2003-12-31 Pfizer Products Inc. Composes benzimidazole et leurs utilisations en tant qu'agonistes/antagonistes des oestrogenes
US7482468B2 (en) * 2005-01-21 2009-01-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine H3 antagonists
WO2016165808A1 (fr) * 2015-04-16 2016-10-20 Merck Patent Gmbh Dérivés de 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509717A2 (fr) * 1991-04-18 1992-10-21 Rhone Poulenc Agriculture Ltd. Compositions herbicides
WO1998006703A1 (fr) * 1996-08-14 1998-02-19 Warner-Lambert Company Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509717A2 (fr) * 1991-04-18 1992-10-21 Rhone Poulenc Agriculture Ltd. Compositions herbicides
WO1998006703A1 (fr) * 1996-08-14 1998-02-19 Warner-Lambert Company Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSUKAMOTO G ET AL: "Synthesis and antiinflammatory activity of some 2-(substituted-pyridinyl)benzimidazoles", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 23, no. 7, July 1980 (1980-07-01), pages 734 - 738, XP002149936, ISSN: 0022-2623 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000817A2 (fr) * 2002-06-24 2003-12-31 Pfizer Products Inc. Composes benzimidazole et leurs utilisations en tant qu'agonistes/antagonistes des oestrogenes
WO2004000817A3 (fr) * 2002-06-24 2004-05-21 Pfizer Prod Inc Composes benzimidazole et leurs utilisations en tant qu'agonistes/antagonistes des oestrogenes
US7482468B2 (en) * 2005-01-21 2009-01-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine H3 antagonists
WO2016165808A1 (fr) * 2015-04-16 2016-10-20 Merck Patent Gmbh Dérivés de 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one
CN107531697A (zh) * 2015-04-16 2018-01-02 默克专利股份公司 3‑(1h‑苯并咪唑‑2‑基)‑1h‑吡啶‑2‑酮衍生物
JP2018511640A (ja) * 2015-04-16 2018-04-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ３−（１ｈ−ベンズイミダゾール−２−イル）−１ｈ−ピリジン−２−オン誘導体
US10179777B2 (en) 2015-04-16 2019-01-15 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives

Also Published As

Publication number Publication date
AU2002216043A1 (en) 2002-05-27
GB0028105D0 (en) 2001-01-03

Similar Documents

Publication Publication Date Title
US20040039198A1 (en) Compounds
US6465493B1 (en) Triarylimidazoles
EP1268465B1 (fr) Derives de triarylimidazole utilises comme inhibiteurs de la cytokine
US20040152738A1 (en) Pyridyl-substituted triazoles as tgf inhibitors
US20030166633A1 (en) Pyridinylimidazoles
US20050014938A1 (en) Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase
US20050165011A1 (en) Benzoxazine and benzoxazinone substituted triazoles
AU2001233918A1 (en) Pyridinylimidazoles
WO2002055077A1 (fr) Utilisation de derives d'acetals d'imidazolyle cycliques dans la fabrication d'un medicament pour le traitement de maladies induites par les recepteurs d'alk5
US20040266842A1 (en) Thiazolyl substituted triazoles as alk5 inhibitors
WO2004111036A1 (fr) 4-(heterocyclyle-phenyle fusionne)-3-phenyle ou pyrid-2-yle)pyrazoles utilises comme inhibiteurs du recepteur de alk-5
WO2002040467A1 (fr) Composes
US20060247233A1 (en) Thiazoles inhibitors of the alk-5 receptor
AU2002363603A1 (en) Phenyl substituted triazoles and their use as selective inhibitors of ALK5 kinase
ZA200206642B (en) Pyridinylimidazoles.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP